Loyola University Chicago

Loyola eCommons
Master's Theses

Theses and Dissertations

2015

Separating Autoimmune and Anti-Tumor Responses with
HSP70iQ435A
James Mahon
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_theses
Part of the Oncology Commons

Recommended Citation
Mahon, James, "Separating Autoimmune and Anti-Tumor Responses with HSP70iQ435A" (2015). Master's
Theses. 3141.
https://ecommons.luc.edu/luc_theses/3141

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2015 James Mahon

LOYOLA UNIVERSITY CHICAGO

SEPARATING AUTOIMMUNE
AND ANTI-TUMOR RESPONSES WITH HSP70iQ435A

A THESIS SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
MASTER OF SCIENCE

PROGRAM IN MICROBIOLOGY AND IMMUNOLOGY

BY
JAMES P. MAHON
CHICAGO, IL
DECEMBER 2015

Copyright by James Mahon, 2015
All rights reserved.

TABLE OF CONTENTS
LIST OF FIGURES .................................................................................................................. v
ABSTRACT .......................................................................................................................... vii
CHAPTER 1: INTRODUCTION .................................................................................................
Vitiligo Background......................................................................................................... 1
HSP70 and Vitiligo ......................................................................................................... 2
HSP70iQ435A .................................................................................................................... 3
Melanoma Background ................................................................................................. 3
Link between HSP70i, Vitiligo, and Melanoma ............................................................. 4
Hypothesis ..................................................................................................................... 6
Specific Aims .................................................................................................................. 6
CHAPTER 2: AIM I
SUB-AIM I: Determine the effect of HSP70iQ435A vaccination on
tumor growth without eliciting depigmentation ........................................................... 8
Experimental Approach ............................................................................................... 8
Results ......................................................................................................................... 9
SUB-AIM II: Determine if HSP70iQ435A vaccination is able to inhibit
depigmentation in vitiligo-prone mice while inhibiting tumor growth ....................... 14
Experimental Approach ............................................................................................. 14
Results ....................................................................................................................... 15
SUB-AIM III: Begin to examine the effects of HSP70iQ435A vaccination in
vitiligo-prone swine to address the bioavailability, safety, and efficacy of a DNA
vaccine designed to treat vitiligo ................................................................................. 19
Experimental Approach ............................................................................................. 19
Results ....................................................................................................................... 21
CHAPTER 3: AIM II
SUB-AIM I: Examine humoral responses to HSP70i after vaccination with the
HSP70iQ435A clinical vector ........................................................................................... 24
Experimental Approach ............................................................................................. 24
Results ....................................................................................................................... 27
SUB-AIM II: Determine which immune cells, if any, are involved
in tumor containment as a result of HSP70iQ435A vaccination. .................................... 29
Experimental Approach ............................................................................................. 29
Results ....................................................................................................................... 32

iii

CHAPTER 4: DISCUSSION .................................................................................................. 38
REFERENCES ..................................................................................................................... 46
VITA .................................................................................................................................. 49

iv

LIST OF FIGURES

Figure

Page

1. Tumor Growth is slowed in mice vaccinated with pUMVC3 vector DNA
encoding WT HSP70i and HSP70iQ435A.

10

2. Mice vaccinated with pUMVC3 vector DNA encoding HSP70i WT
and HSP70iQ435A show reduction in average tumor mass.

11

3. Trend toward decreased melanoma tumor growth seen in mice vaccinated
with TOPO vector DNA encoding WT HSP70i and HSP70iQ435A.

12

4. Mice vaccinated with both forms of HSP70i in TOPO vector show a trend in
reduction of tumor mass.

13

5. Average tumor growth rates from PMEL-1 mice following DNA-vaccinations
and tumor challenge.

15

6. Final average tumor mass from PMEL-1 mice following DNA-vaccinations
and tumor challenge.

16

7. Images of PMEL-1 depigmentation over the course of the study.

17

8. PMEL-1 average depigmentation over the course of the study
might be trending toward decreased average depigmentation in
HSP70iQ435A vaccinated mice.

18

9. Treatment with DNA-vaccine encoding HSP70iQ435A can induce
repigmentation of lesional vitiligo in swine.

21

10. Treatment with DNA-vaccine encoding HSP70iQ435A can induce
repigmentation of lesional vitiligo in swine.

22

v

11. B cell Transfer from vaccinated to tumor-challenged mice confers
tumor resistance.

27

12. B cell Transfer to tumor challenged SCID/Beige immunodeficient mice
confers tumor resistance.

28

13. Vaccination with pUMVC3 vector DNA encoding HSP70i WT and
HSP70iQ435A promotes T-Cell infiltration.

32

14. Vaccinated mice produce more robust antibody response toward
HSP70i when compared to unvaccinated mice.

33

15. Treatment with DNA-vaccine encoding HSP70iQ435A can inhibit
CD3+ T cell infiltration in lesional vitiligo skin.

34

16. Treatment with DNA-vaccine encoding HSP70iQ435A can inhibit
CD3+ T cell infiltration in lesional vitiligo skin over time.

35

17. HSP70i DNA-treatment in pigs can produce an antibody response
toward HSP70i.

36

18. HSP70i DNA-treatment in swine can raise serum levels of HSP70i protein
beyond basal levels.

37

19. Mutant HSP70iQ435A promotes anti-tumor immunity while
preventing auto-immunity.

44

vi

ABSTRACT
Vitiligo is described as an autoimmune-mediated skin disorder in which
melanocytes are targeted and killed by cytotoxic lymphocytes, resulting in
depigmentation of the skin. One cause of vitiligo progression is when stressed or damaged
melanocytes release a 70kDa stress-induced heat shock protein (HSP70i) carrying
melanocyte protein; this activates nearby dendritic cells toward an inflammatory
phenotype which circulate through the lymph and prime a cytotoxic response against
melanocyte antigen. The Le Poole lab previously identified a peptide within HSP70i
responsible for activating this inflammatory phenotype in human DCs and developed
HSP70iQ435A. It was found that treatment with HSP70iQ435A is able to prevent proliferation
of the vitiligo-associated inflammatory DC phenotype, thus preventing accumulation of
melanocyte antigen-specific T cells in the skin and reducing depigmentation in mice.
However, because treatment with HSP70iQ435A inhibits this DC-mediated autoimmune response against melanocytes in vitiligo mouse models, there existed a valid
concern that treatment with this modified heat shock protein may also inhibit natural
anti-tumor responses against melanocyte-derived melanoma tumor cells. Therefore, the
first hypothesis of this project is that HSP70iQ435A prevents migration of melanocyteantigen reactive T cells to the skin in a way that is mechanistically different from antitumor responses to melanoma and therefore would not have a negative effect on antivii

tumor responses. Using data gathered from testing this first hypothesis, a second
hypothesis was established, proposing that treatment with HSP70i Q435A confers antimelanoma resistance through antibody-dependent cell-mediated cytoxicity.
To test the first hypothesis, BL/6 mice were treated with DNA-vaccines encoding
WT HSP70i, HSP70iQ435A, or were not vaccinated for 5 weeks and then tumor-challenged
with B16 mouse melanoma. Results from several of these vaccination/tumor-challenge
mouse experiments displayed that treatment with both WT HSP70i and HSP70i Q435A
inhibit tumor growth in the subsequent tumor challenge when compared to the nonvaccinated mice. CD3 T cell migration to the melanoma was not negatively affected in the
treated mice. Surface staining of B16 melanoma cells also revealed surface expression of
HSP70i, consistent with past observations of tumor cell overexpression and surface
expression of heat shock proteins. These data suggest that anti-tumor responses
following treatment with HSP70iQ435A are not inhibited but actually strengthened, and this
anti-tumor response may be related to the overexpression of HSP70i common to tumor
cells.
To test the second hypothesis, B-Cells were adoptively transferred from HSP70i
DNA-vaccinated BL/6 mice into naïve BL/6 that then received a tumor challenge. Results
displayed that mice receiving the adoptively transferred B cells had decreased tumor
growth rates and final tumor mass, when compared to tumor-challenged mice that did
not receive adoptively transferred cells. Furthermore, serum taken from vaccinated
animals (mouse and swine) show increased levels of anti-HSP70i antibody. Taken
together, these data suggest that HSP70iQ435A polarizes dendritic cells to support
viii

antibody-mediated responses to surface HSP70i expressed by tumor cells while
preventing migration of melanocyte-antigen reactive T cells to the skin.

ix

CHAPTER 1
INTRODUCTION
Vitiligo Background
Vitiligo is described as an autoimmune-mediated skin disorder in which
melanocytes are killed, resulting in depigmentation of the skin. During vitiligo,
melanocytes are destroyed by melanocyte-reactive T cells, as well as other immune or
non-immune components (1). Expanding vitiligo lesions are consistently infiltrated with T
cells in the areas lining the lesional borders; these infiltrating T cells are composed
primarily of CD8+ cytotoxic T cells reactive with melanocyte-specific antigens (2).
Moreover, increased numbers of inflammatory CD11c+ dendritic cells have been
observed in the lesional skin of vitiligo patients, which are thought to lend to the increased
auto-immune response leading to vitiligo (3).
However, problems arise in the development of effective therapeutics for the
disease because re-establishing pigmentation in patients with active disease would likely
be problematic without first halting progression of the disease; in this sense,
understanding the cellular mechanisms behind depigmentation in vitiligo disease became
a key focus of vitiligo studies.
Previous research into the mechanisms behind vitiligo progression has
demonstrated a link between stress-induced heat shock proteins as players involved in
1
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the autoimmune responses responsible for vitiligo (5). Primary among these immuneactivating stress proteins are HSPs 60, 70, and 90 (5). Certain HSPs assist in normal cellular
functions such as protein-misfold repair; others are synthesized only under stress (12). Of
interest among these stress-inducible HSPs is an inducible form of Heat Shock Protein 70
(HSP70i, also known as HSP72) which is known to be secreted from live cells through an
active-release mechanism (9). Under standard physiological conditions, the constitutive
isoform of HSP70 (HSC70) is expressed within the cell offering cytoprotection to the cell
through assisting in chaperoning misfolded proteins. However, through cell death or
active secretion, an inducible isoform of HSP70 (HSP70i) can be released into the
extracellular environment where it is then able to interact with dendritic cells to enhance
the uptake of antigens (7). This implies that an auto-immune response to HSP70i, and any
proteins it may be chaperoning, can occur even in the absence of cell death.
HSP70 and Vitiligo
In vitro studies have associated HSP70 as a factor in the formation of the vitiligo
disease state: melanocytes were shown to overexpress HSP70 in response to the
bleaching agent 4-tertiary butyl phenol (4-TBP), a compound used in rubber manufacture
and the photoindustry, which is selectively cytotoxic to melanocytes within the skin and
induces depigmentation in vitiligo patients sensitive to these agents (3). Increased
amounts of HSP70 were detectable in the supernatant of vitiligo melanocytes compared
to control melanocytes (3). Studies comparing the lesional and non-lesional skin of three
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vitiligo patients show consistent differential expression of HSP70 as observed by
immunohistological staining, further implying that HSP70 plays a role for in autoimmuneinduced depigmentation of melanocytes (8).
HSP70iQ435A
Previously, the Le Poole lab identified a peptide within the stress-inducible HSP70i
responsible for activating human dendritic cells and developed HSP70iQ435A, a mutant
DNA isoform with a single amino acid modification. Located on the outer cusp of the
substrate binding domain in 3D models of the protein, just outside the substrate binding
groove, this change in amino acid 435 affects activation of DCs following binding with the
stress protein. It was found that vaccination with this mutant form of HSP70
(HSP70iQ435A) is able to prevent proliferation of the vitiligo-associated inflammatory
dendritic cell phenotype, thus preventing accumulation of melanocyte antigen-specific T
cells in the skin and reducing depigmentation in mice (4). These findings suggested that
the mutant form HSP70i is not only an inactive variant but also binds DCs and alters their
function in such a way that interferes with later T cell activation. The implications of this
study are that HSP70iQ435A DNA delivery may be used for the treatment of vitiligo (4).
Melanoma Background
While vitiligo deals with melanocyte death, at the other end of the spectrum we
have the uncontrollable proliferation of melanocytes in the form of melanoma skin
cancer. Skin cancer, the current most common malignancy across the world, is often
classified as either non-melanoma skin cancer (NMSC) or melanoma skin cancer (14).
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NMSC, which is rarely lethal, accounts for the majority of skin cancer cases, with the most
common types being basal cell cancer and squamous cell cancer. Malignant melanoma
skin cancer, while accounting for only ~4% of all skin cancers, is the major cause of death
from skin cancer (15). Melanoma is derived from pigment-producing melanocytes which,
within in the skin, are found at the basal level of the epidermis (14). Immune suppression
in the skin, induction of uncontrolled melanocyte cell division, or DNA damage of growth
regulatory genes caused by sources such as UV radiation or reactive oxygen species (16)
all contribute to the development and progression of melanoma. While non-metastatic
melanoma can be treated with surgical removal if detected early, later stage metastatic
malignant melanoma is extremely difficult to treat with existing cancer therapies and
often has a poor prognosis, with a median survival rate of 6 months and a 5-year survival
rate of less than 5% (15). In 2012, the American Cancer Society reported 1.6 million new
cases of skin cancer, with about 76,000 of those cases diagnosed as melanoma; of the
12,190 deaths caused by skin cancer in 2012, almost 9,200 were caused by melanoma
(14). For a malignant melanoma cell to be successful it must persist in incredibly highstress environments; under these difficult conditions, melanoma cells often upregulate
stress proteins as a means of promoting protein homeostasis and cellular viability (13).
Link between HSP70i, Vitiligo, and Melanoma
The overexpression of HSP70i in these tumor cells is often associated with
secretion and membrane-expression of stress proteins with evidence to suggest that
HSP70i is one of these stress proteins is that is overexpressed and expressed on the
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membrane of primary and metastatic melanoma cells but not normal cells; as such,
HSP70i may be a viable target for anti-melanoma therapeutics (10). This information
becomes even more exciting when you consider that vitiligo is known to be an
unavoidable side-effect of certain melanoma therapeutics which target melanomaantigen, as there is often crossover between antigen expressed on melanoma cells and
antigen expressed on melanocytes, resulting in an immune response toward the
melanoma cell that collaterally attacks healthy melanocytes. With this in mind, there is a
concern that treatment for vitiligo with this mutant HSP70i may alter the autoimmune
response in such a way that the immune cells directly affected by HSP70i interaction (DCs,
T-Cells) would not as effectively target melanoma tumor.

6

HYPOTHESIS
HSP70iQ435A polarizes dendritic cells to support B cell responses to surface HSP70i
expressed by tumor cells while preventing migration of melanocyte-antigen reactive T
cells to the skin.

The following specific aims were established to test the hypothesis.
SPECIFIC AIMS
Aim I: Measure melanoma and vitiligo development in response to HSP70i Q435A
vaccination.
These experiments will help shed light on the consequences of HSP70iQ435A vaccination
with regards to anti-melanoma immunity, and whether or not tumor containment is
affected by this change in auto-immunity.
Sub-Aim I: Determine the effect of HSP70iQ435A vaccination on tumor growth without
eliciting depigmentation.
Vaccinate WT C57BL/6 mice with HSP70iQ435A and challenge with B16-F10 melanoma
cells, following tumor growth and depigmentation over time.
Sub-Aim II: Determine if HSP70iQ435A vaccination is able to inhibit depigmentation in
vitiligo-prone mice while inhibiting tumor growth.
Vaccinate PMEL-1 mice and challenge with B16 melanoma cells, following tumor growth
and depigmentation over time.
Sub-Aim III: Begin to examine the effects of HSP70iQ435A vaccination in vitiligo-prone
swine to address the bioavailability, safety, and efficacy of a DNA vaccine designed to
treat vitiligo.
Treat swine vitiligo lesions with DNA vaccine and assess changes in lesional size over
time.

7

Aim II: Establish the cell(s) responsible for tumor containment and depigmentation.
These experiments will help us understand the mechanism by which treatments with
the DNA-vaccines encoding HSP70iQ435A and WT HSP70i are able to promote antimelanoma responses in mice.
Sub-Aim I: Examine humoral responses to HSP70i after vaccination with the
HSP70iQ435A clinical vector.
Immune monitoring of available serum and relevant tissues from animals after
HSP70iQ435A vaccination or adoptive transfer.
Sub-Aim II: Determine which immune cells, if any, are involved in tumor containment
as a result of HSP70iQ435A vaccination.
Vaccinate WT C57BL/6 mice with HSP70iQ435A and adoptively transfer immune cells from
the vaccinated mice to B16-challenged SCID/beige immune-deficient recipient mice.

CHAPTER 2
AIM I: Measure melanoma and vitiligo development
in response to HSP70iQ435A vaccination.
SUB-AIM I: Determine the effect of HSP70iQ435A vaccination
on tumor growth without eliciting depigmentation.

EXPERIMENTAL APPROACH
To prepare the bullets for gene gun vaccination, 100 μg of endotoxin-free plasmid
DNA of both WT HSP70i and HSP70iQ435A (prepared in pUMVC3 DNA vector, designed by
the University of Michigan’s Vector Core) was precipitated onto spermidine-coated gold
micro-particles in the presence of 200mM CaCl2 and washed with 6 volumes of ethanol.
Washed beads were precipitated onto silicone tubing in a BioRad Tubing Prep Station and
prep. The DNA-coated tubing was cut into sections that fit the Helios Gene Gun (BioRad),
with about 1.2 μg of DNA per bullet. Bullets were used within 2 weeks of preparation.
WT C57BL/6J mice (Jackson Labs, Bar Harbor, ME) were used in this experiment.
The mice were separated into 3 vaccination groups: control, WT HSP70i, and HSP70iQ435A.
For each group, n=6. Mice were prepared for gene gun vaccination by biweekly ventral
hair removal with Nair. The mice were anesthetized using 5% isoflurane and vaccinated
with four bullets each (4.8 μg of DNA) for five consecutive weeks (one vaccination every
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6 days). During gene gun vaccination with the Helios Gene Gun, gold micro-particles
coated with DNA are released from silicon tubing cartridges under helium pressure at a
maximum of 300 p.s.i., which allows for the DNA to directly enter the skin and nestle
inside relevant cell types such as DC, where the DNA is mechanically transfected and
expressed.
One week after the final vaccination, the mice were sub-cutaneously challenged
with 105 cells of the B16 mouse melanoma cell line; the tumors were injected near the
sites of vaccination, once in the left flank and once in the right flank of each mouse. Tumor
progression was followed over the next several weeks using a pair of calipers to
determine tumor volume in each mouse. Two weeks after the first sign of a palpable
tumor (which took 8 days to emerge post-injection) the mice were sacrificed; their final
tumor volumes were measured and the tumors were harvested to be weighed for mass
and cryopreservation.
RESULTS
The experiment outlined in the experimental approach is a repeat of a vaccination
experiment performed during my initial rotation in the lab; during this initial vaccination
the mice were vaccinated with WT HSP70 in TOPO 3.1 GFP vector and HSP70iQ435A in TOPO
3.1 GFP vector (rather than pUMVC3 vector, as described in the previous experimental
approach section). It was repeated again using the pUMVC3 vector because the pUMVC3
vector is approved for clinical trials while the TOPO 3.1 vector is not.
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In the pUMVC3 vector vaccinated mice, tumor progression was followed after the
first sign of tumor growth (Day 0). When compared to the unvaccinated mice, the
vaccinated mice displayed a longer onset of tumor growth (by about 3 days), an average
decreased tumor growth rate as a measure of volume, and smaller tumors on average as
a measure of volume (66% decrease in final tumor size for the HSP70iQ435A vaccinated
mice, 62% decrease in final tumor size for the WT HSP70i vaccinated mice).

Figure 1: Tumor Growth is slowed in mice vaccinated with pUMVC3 vector DNA
encoding WT HSP70i and HSP70iQ435A.

As seen in Figure 1, the difference in combined tumor volume by the end of the
experiment displayed significance for both vaccination groups (p=0.0143 between
Control and HSP70iQ435A, p=0.0262 between Control and WT HSP70i). Final tumor volumes
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were analyzed for significance using an unpaired, two-tailed T-Test with a confidence
interval of 95%. (n = 6 for each group).

Figure 2: Mice vaccinated with pUMVC3 vector DNA encoding HSP70i WT and
HSP70iQ435A show reduction in average tumor mass.

After sacrifice of the animals, the tumors were harvested, weighed, and the
average tumor masses per vaccination group were compared. As seen in Figure 2, a
student’s T-Test revealed a significant 70% decrease in average tumor mass of the
HSP70iQ435A vaccinated animals when compared to the control animals (p=0.0273), while
the WT HSP70i vaccinated animals trended toward a smaller average tumor mass than
the control animals but did not reach significance (p=0.0881).
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Figure 3: Trend toward decreased melanoma tumor growth seen in mice vaccinated with
TOPO vector DNA encoding WT HSP70i and HSP70iQ435A.

For reference, tumor growth data from the original TOPO vector vaccinated mice
are included as follows. The vaccinated mice represented in Figure 3 displayed a longer
onset of tumor growth, an average decreased tumor growth rate as a measure of volume,
and smaller tumors on average as a measure of volume. The vaccinated mice trended
towards smaller average tumor volumes when compared with the average tumor volume
of unvaccinated mice (p=0.1886 between Control and HSP70iQ435A, p=0.1881 between
Control and WT HSP70i) (n = 5 for each group).
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Figure 4: Mice vaccinated with both forms of HSP70i in TOPO vector show a trend in
reduction of tumor mass.

As seen in Figure 4, the difference in both the average tumor mass of the
HSP70iQ435A vaccinated animals and the average tumor mass of the WT HSP70i vaccinated
animals trended toward a smaller tumor mass than the tumors of the control animals, but
did not reach significance (p=0.1765 for the HSP70iQ435A vaccinated animals, p=0.1918 for
the WT HSP70i vaccinated animals). (n = 5 for each group)
Together, these data showing significantly decreased tumor growth rates and final
tumor mass in the vaccinated mice indicate that anti-melanoma responses are not
inhibited, but strengthened by vaccination with both forms of HSP70i.
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SUB-AIM II: Determine if HSP70iQ435A vaccination is able to inhibit depigmentation in
vitiligo-prone mice while inhibiting tumor growth.
EXPERIMENTAL APPROACH
The mice used in this experiment are transgenic PMEL-1 mice, which carry T cells
with a rearranged T cell receptor specific for the mouse homologue (pmel-17) of human
melanocyte protein gp100 and naturally develop vitiligo (11). Prior to vaccination the
mice were imaged (dorsally and ventrally) using a photo-scanner to measure prevaccination pigmentation. Gene Gun bullet preparation and Gene Gun vaccinations were
carried out as described in Aim I: Sub-Aim I. Mice were DNA-vaccinated with either 2.4μg
of WT HSP70i in pUMVC3 plasmid DNA, or 2.4ug of HSP70iQ435A in pUMVC3 plasmid DNA.
Due to time constraints, each mouse was also DNA-vaccinated with 2.4ug of hGP100 in
TOPO plasmid DNA; this was done to facilitate depigmentation. The mice received 5
vaccinations every 6 days, followed by 2 booster vaccinations 4 days apart. Over the
course of the vaccinations, the mice were imaged using the photo-scanner immediately
prior to their biweekly hair-removals.
One week after the final vaccination, the mice were sub-cutaneously tumor
challenged with 105 B16 mouse melanoma cells as described in Aim I: Sub-Aim I. Tumor
progression was followed as a measure of volume while the mice were alive, and
pigmentation was measured just before sacrifice. Tumors were harvested from the mice
upon sacrifice and weighed for mass and cryopreservation. Statistical analysis was
conducted on average final tumor volumes as well as average tumor masses to determine
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the

effect

of

HSP70i/

HSP70iQ435A

on

tumor

containment.

Depigmentation/Repigmentation was also be analyzed using scans taken before, during,
and after treatment.
RESULTS

Figure 5: Average tumor growth rates from PMEL-1 mice following DNA-vaccinations
and tumor challenge.

Tumor growth was measured after the first sign of tumor growth in WT HSP70i
vaccinated mice on Day 12, and Day 13 in HSP70iQ435A vaccinated mice. As seen in Figure
5, the mice vaccinated with HSP70iQ435A displayed a longer onset of tumor growth and
smaller tumors on average as a measure of volume when compared to the mice
vaccinated with WT HSP70i, though not significantly different (n = 10 for each group).
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Figure 6: Final average tumor mass from PMEL-1 mice following DNA-vaccinations and
tumor challenge.

As seen in Figure 6, the average final tumor mass of the HSP70iQ435A vaccinated
mice was 0.8g while the average final tumor mass of the WT HSP70i vaccinated mice was
1g; the average final tumor mass of the HSP70iQ435A vaccinated mice was decreased, but
not significantly different when compared to the WT HSP70i vaccinated mice. This data
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further suggests that tumor containment is not impeded by DNA-vaccination with the
mutant HSP70iQ435A.

Figure 7: Images of PMEL-1 depigmentation over the course of the study.

Figure 7 shows images of mice taken immediately prior to treatment (Week 0) and
immediately prior to sacrifice (Week 10). Areas of depigmentation can be seen along the
abdomen where DNA vaccination took place (n = 10 for each group).
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Figure 8: PMEL-1 average depigmentation over the course of the study might be
trending toward decreased average depigmentation in HSP70iQ435A vaccinated mice.
Depigmentation was analyzed as a measure of luminosity level change when
compared to the individual animal’s starting levels measured at 4.22. As seen in Figure 8
at the 6.04 time point, the WT HSP70i vaccinated mice display an average of 46%
depigmentation, while the HSP70iQ435A vaccinated mice display an average of 38%
depigmentation, a 1.2 fold increase in WT over Q435A. At the 7.08 time point, the WT
HSP70i vaccinated mice display an average of 55% depigmentation, while the HSP70iQ435A
vaccinated mice display an average 46% depigmentation, a 1.2 fold increase in WT over
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Q435A. (n = 10 for each group). These depigmentation data indicate a small decrease in
depigmentation in the HSP70iQ435A treated mice, but no significant difference.

SUB-AIM III: Begin to examine the effects of HSP70iQ435A vaccination in vitiligo-prone
swine to address the bioavailability, safety, and efficacy of a DNA vaccine designed to
treat vitiligo.
Bringing HSP70iQ435A closer to the clinic, our lab plans to introduce and track the
HSP70iQ435A vaccine in swine with human-like skin and manipulate tumor growth and
depigmentation in response to wild type and mutant HSP70i in Sinclair swine with
spontaneous melanomas and vitiligo to address the microenvironmental signature of
relevant sites.
EXPERIMENTAL APPROACH
Animals were treated weekly with 5 mg of the drug for a total of 4 weeks. A
PharmaJet injector is being used to deliver 4 doses of 0 (control) or 1.25 mg/mL DNA in
0.5 mL each to the border of a single, preselected lesion. Animals were followed for 6
months from the first DNA vaccination. The primary objectives were to measure changes
in lesional expansion (relative to the injection sites) by biweekly grid measurements and
to follow drug distribution and local and systemic reactivity over time. Biweekly 50ml
blood draws will be accompanied by monthly perilesional biopsies under local lidocaine
anesthesia from treated and untreated perilesional skin before, during, and after
treatment. For blood sampling and biopsies, pigs are secured and anesthetized with 2-4%
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isoflurane using a mask. 4 mm biopsies were taken and skin were sutured with Vycril
sututre or vetbond tissue adhesive, accompanied by topical application of triple antibiotic
ointment as a preventive measure against infection. Animals were monitored until
conscious before returning them to their cage, hourly thereafter until the animal
appeared calm, and every next day until suture removal. Biopsies were snap-frozen on
dry ice and stored at -80c until needed for cryosectioning and tissue staining. The pigs and
lesional areas are followed for progressive depigmentation or repigmentation, similar to
testing planned in human subjects, wherein grid measurements are made to quantify
lesional area (including both treated and untreated lesions) at 2 week intervals before
and after vaccination. At euthanasia, major tissues will be collected, screened, and
evaluated for drug content. Remaining melanoma tumor mass will be measured. Tissues
collected are stored frozen for further analysis of antibody titers by ELISA, and
immunostaining to quantify immune infiltrates according to parameters previously
established in mice [see Aim II: Sub-Aim II results].
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RESULTS

Figure 9: Treatment with DNA-vaccine encoding HSP70iQ435A can induce repigmentation
of lesional vitiligo in swine.

Lesional areas of interest were measured over the course of the study and changes
in the vaccination-site lesion are represented in Figure 9. As seen in these data, the DNA
treated swine in Group #1 displayed a very significant decrease (p = 0.0001) in vitiligo
lesional area when comparing the starting time point with the final time point, decreasing
in size 75% over the course of 27 weeks (9a). The Group #1 and group #2 PBS swine
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showed increasing melanoma lesional size (9b, 9d). The Group #2 DNA treated swine
displayed a 300% increase in lesional size (9c).

Figure 10: Treatment with DNA-vaccine encoding HSP70iQ435A can induce repigmentation
of lesional vitiligo in swine.
Figure 10 shows images of treated vitiligo lesions on both of the DNA treated
swine; the images for the Group #1 swine were taken at Week 1 [10a] and Week 27 [10b]
while the images for the Group #2 swine were taken at Week 1 [10c] and Week 18 [10d].
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The Group #1 swine displayed a significant regression of its vitiligo lesion between Week
1 [10a] and Week 27 [10b], regressing about 78% from its original size. The Group #2 DNA
treated swine displayed a 300% increase in lesional size from Week 1 [10c] to Week 18
[10d]. These data from the DNA vaccinated swine in Group #1 suggest a positive response
to the drug in terms of vitiligo inhibition and regression.

CHAPTER 3
AIM II: Determine the contribution of B cells to tumor containment and depigmentation.
SUB-AIM I: Determine which immune cells, if any, are involved in tumor containment
as a result of HSP70iQ435A vaccination.

From these experiments I am hoping to gain further insight into which immune
cells are involved in tumor containment following a vaccination with HSP70i/ HSP70iQ435A.
This involves the transfer of cells from vaccinated mice to naïve, tumor-challenged mice.
The cells being transferred are CD8+ T-Cells, CD11c+ Dendritic Cells, and B220+ B cells. A
second adoptive cell transfer experiment involved the transfer of cells from
HSP70i/HSP70iQ435A vaccinated C57BL/6J mice into tumor-challenged immunodeficient
SCID-beige mice. SCID-beige mice were used due to their lack of a functional immune
system which can help decipher whether an individual cell type is soley responsible for
anti-tumor protection during the adoptive cell transfer.
EXPERIMENTAL APPROACH
WT C57BL/6J mice are being used in this experiment; for each experimental group,
n=5. There are 2 vaccination groups, 6 recipient groups, and 1 control group. The
vaccination groups are prepared and Gene Gun vaccinated for five weeks with either WT
HSP70i or HSP70iQ435A (in pUMVC3 DNA vector) as described in Aim I: Sub-Aim I.
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One week after the final vaccination, these two vaccination groups were sacrificed
and their spleens were removed for splenocyte harvest. The spleens were homogenized
using a 70μm Nylon Mesh sterile cell strainer and washed with ice-cold HBSS; the spleen
homogenates were pooled together according to vaccination group (product is kept on
ice during the splenocyte harvest). ACK Lysis Buffer was used to lyse red blood cells from
the homogenate and DNase was used to reduce clumping. Cells were washed with icecold media then pelleted and resuspended in media. Cells were counted in preparation
for sorting with MACS Separation Beads (Magnetic-Activated Cell Sorting). CD11c+
Dendritic Cells were sorted out first, followed by CD8+ T-Cells, and finally B220+ B cells.
Using CD11c+ DC sorting as an example, the splenocytes were magnetically labeled with
magnetic MicroBeads conjugated to anti-CD11c antibodies. The cell suspension is loaded
into a column which is attached to a magnetic MACS Separator. The suspension flows
through the column and the magnetically labeled cells are retained within the column,
while the unlabeled cells flow through. The flow-through is kept on ice for further
separation of CD8+ T-Cells and B220+ B cells. The column is then removed from the
magnetic field and the magnetically labeled CD11c+ DCs are eluted through and kept on
ice. This process is repeated using CD8 MicroBeads and B220 MicroBeads.
At this point, there are 6 cell fractions: DCs, CD8 T-Cells, and B cells from WT
HSP70i vaccinated mice as well as DCs, CD8 T-Cells, and B cells from HSP70iQ435A
vaccinated mice. The cell fractions are counted, resuspended at 106 cells/100μL, and kept
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on ice for immediate retro orbital injection into the recipient mice. The recipient mice are
anesthetized using 5% isoflurane and receive 106 cells (Cell type is dependent upon their
recipient group) via periorbital injection. After cell-transfer injections are complete, the
mice were challenged with 105 B16 mouse melanoma cells, sub-cutaneously in their right
flank. A control group of mice did not receive transferred cells, but did receive the tumorchallenge. Tumor progression was followed as a measure of volume and, upon sacrifice,
the tumors were harvested and weighed to measure tumor mass.
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RESULTS

Figure 11: B cell Transfer from vaccinated to tumor-challenged mice confers tumor
resistance.

In Figure 11, a student’s T-Test revealed that tumor-challenged BL/6 mice that
received B cells from the WT HSP70i DNA-vaccinated mice displayed a significant 75%
decrease (p=0.016) final tumor mass when compared to the average final tumor mass
from BL/6 mice receiving B cells from unvaccinated BL/6 mice. Tumor-challenged BL/6
mice that received B cells from Mut HSP70i DNA-vaccinated mice also displayed a
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significant 60% decrease (p=0.039) in final tumor mass when compared to the average
final tumor mass from BL/6 mice receiving B cells from unvaccinated BL/6 mice (n = 7 for
each group).

Figure 12: B cell Transfer to tumor challenged SCID/Beige immunodeficient mice confers
tumor resistance.

In Figure 12, a student’s T-Test revealed a 83% significant decrease (p=0.032) in
average final tumor mass for the tumor-challenged SCID-beige mice that received B cells
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from WT HSP70i DNA-vaccinated BL/6, when compared to the average final tumor mass
from SCID-beige mice receiving no cell transfer. Tumor-challenged SCID-beige mice that
received B cells from Mut HSP70i DNA-vaccinated BL/6 mice displayed a 90% significant
decrease (p=0.022) in final tumor mass when compared to the average final tumor mass
from SCID-beige mice receiving no cell transfer. Tumor-challenged SCID-beige mice that
received B cells from unvaccinated BL/6 mice displayed a 91% significant decrease
(p=0.021) in final tumor mass when compared to the average final tumor mass from SCIDbeige mice receiving no cell transfer (n = 5 for each group).

SUB-AIM II: Examine humoral responses to HSP70i after vaccination
with the HSP70iQ435A clinical vector.
This Sub-Aim is linked to Aim I (Sub-Aim I, Sub-Aim II, and Sub-Aim III) and most
of the data generated for this experimental question was analysis from harvested tissue
and serum from these previously mentioned mouse/swine vaccination experiments and
adoptive transfer experiments.
EXPERIMENTAL APPROACH
At the time of sacrifice, tissue harvesting of mouse skin and tumor were placed in
OCT compound and snap-frozen on dry ice, spleens were harvested and homogenized,
and a sample of blood was taken. The blood was allowed to coagulate and then spun
down 2x to harvest serum.
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Swine tissue was collected monthly using a 4mm Acu-Punch biopsy tool; a biopsy
was taken from the perilesional region of the vitiligo and a second biopsy was taken from
the contralateral flank. 50mls of swine blood was collected bi-weekly; it was allowed to
coagulated and then spun down 2x to harvest serum.
For immunohistological staining of tissue sections, 8 μm cryostat sectioned tissues
were fixed in cold acetone and stored at −20 °C until use. Upon use, the tissues were
stained using an immunohistological single stain method (using either HRP- or APconjugated antibody, and the respective detection solution) or immunofluorescence stain
method (using fluorophore-conjugated antibody). The stained tissue sections were
imaged on the compound microscope for immunohistological staining or fluorescent
microscope for IF staining (at least 7 images taken per slide) and quantified. Mouse tissue
was stained with monoclonal, PE-conjugated, hamster IgG antibody specific to the epsilon
chain of mouse CD3. Swine tissue was stained with a primary, PE-Cy5-conjugated, mouse
IgG1 antibody against the epsilon chain of swine CD3 from manufacturer Abcam; a
secondary stain used PE-conjugated, polyclonal rabbit antibody against mouse IgG from
manufacturer Dako.
To visualize relative levels of anti-HSP70i in mouse serum after the vaccination
experiments, purified HSP70i protein was run through an agarose gel using gel
electrophoresis; the protein was then transferred from the gel to a PVDF membrane.
Frozen mouse sera from the vaccination experiments outlined in Aim I: Sub-Aim I was
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used to probe the membrane, alongside known anti-HSP70i antibodies SPA810 and
SPA820. Dako-manufactured polyclonal, AP-conjugated Goat anti-Mouse IgG was used as
a secondary to detect bound mouse antibody from the sera probe. AP detection solution
was used for development of the membrane and visualization of HSP70i bound mouse
antibody.
Humoral responses to autologous and vaccinated HSP70i/HSP70iQ435A will be
measured in swine sera by ELISA. To quantify levels of anti-HSP70i antibody in swine
serum, an anti-HSP70 ELISA kit from Enzo Life Sciences was used. Swine serum was
applied to the HSP70-coated wells, the wells were washed, a secondary, HRP-conjugated
Goat anti-Swine IgG antibody was and, after washing, the TMB substrate is added to
measure concentration of HRP-conjugated secondary bound to anti-HSP70i antibody
from swine sera. To quantify levels of HSP70i protein in the swine serum, an HSP70 high
sensitivity ELISA kit from Enzo Life Sciences was used. Swine serum was applied to the
wells which were coated with anti-HSP70 antibody. After washing, a primary anti-HSP70
antibody was added, the plates are later washed, and an HRP-conjugated secondary
antibody specific to the primary antibody is added. The plate is washed and the substrate
is added to measure concentration of HRP-conjugated secondary bound to anti-HSP70
primary bound to HSP70 from the swine sera.
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RESULTS

Figure 13: Vaccination with pUMVC3 vector DNA encoding HSP70i WT and HSP70iQ435A
promotes T-Cell infiltration.

In Figure 13, the CD3+ T-Cell quantification of tumor sections from the vaccination
experiment outlined in Aim I: Sub-Aim I show a trend toward increased amounts of CD3+
T-Cells at the periphery of the tumors of WT HSP70i vaccinated mice (p=0.0643), with a
50% increase in CD3+ T-Cells as compared to the quantification of CD3+ T-Cells in the
tumor tissues from the non-vaccinated mice. A student’s T-Test revealed a significant 80%
increase (p=0.0086) in CD3+ T-Cells at the periphery of the tumors from HSP70iQ435A
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vaccinated mice, when compared to the quantification of CD3+ T-Cells at the periphery
of tumor tissues from the non-vaccinated mice.

Figure 14: Vaccinated mice produce more robust antibody response toward HSP70i
when compared to unvaccinated mice.

Figure 14 shows the results of a Western Blot where serum from vaccination-study
mice (Aim I: Sub-Aim I) was used as a probing antibody against purified immunoblotted
HSP70i protein. Known anti-HSP70 antibodies, SPA-810 and SPA-820, were included as
positive controls. When compared to the mice that were not vaccinated, the sera from
vaccinated mice seem to contain a very robust antibody response toward HSP70i, around
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a 400% increase in band density as measured in ImageJ; this was seen most in the sera
taken from mice vaccinated with HSP70i in pUMVC3 vector.

Figure 15: Treatment with DNA-vaccine encoding HSP70iQ435A can inhibit CD3+ T cell
infiltration in lesional vitiligo skin.

Swine CD3+ T cells were quantified and measured as CD3+ T cells/mm2 of the
biopsy area; as we took monthly biopsies, this allowed us follow changes over time in the
CD3+ T cell count at the periphery of the lesional areas, as represented in Figure 15. The
DNA treated swine from Group #1 exhibits a significant 83% decrease (p=0.007) in CD3+
T cell counts between weeks 4 and 8, which coincides with the end of its DNA treatments.
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The CD3+ T cell count slowly begins to rise but plateaus at around 30 CD3+ T cells/mm 2
and does not rise back to original levels observed in the first week [15a]. The PBS treated
swine from Group #1 does not display any major increases or decreases in CD3+ T cell
counts at the periphery of its melanoma lesional area over the course of 24 weeks [15b].
The DNA treated swine from Group #2 does not display significant changes while the CD3+
T cell counts of the PBS treated swine from group #2 steadily climbs over the course of 20
weeks [15c-d].

Figure 16: Treatment with DNA-vaccine encoding HSP70iQ435A can inhibit CD3+ T cell
infiltration in lesional vitiligo skin over time.

Figure 16 displays the data from Swine Group #2 as the average CD3+ T cell counts
of each respective treatment with each week represented as fold change from Week 0.
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Figure 17: HSP70i DNA-treatment in pigs can produce an antibody response toward
HSP70i.

Through an ELISA using sera taken from the swine, it was revealed that the DNA
treated swine from Group #2 produced a significant, 300% increase in anti-HSP70i
antibody between the first week of treatment and the fourth and final week of treatment;
that elevated level of antibody remained into week 6, and began dropping back to basal
levels around week 8 as seen in Figure 17. The remaining swine did not display any
significant changes in anti-HSP70i antibody concentration.
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Figure 18: HSP70i DNA-treatment in swine can raise serum levels of HSP70i protein
beyond basal levels.

Figure 18 shows the results of an ELISA run with sera taken from the swine to
detect serum level HSP70i protein in the swine vaccinated with HSP70iQ435A DNA vaccine.
It was revealed that the DNA treated swine from Group #2 produced a significant increase
(p=0.0003) in serum HSP70i protein between week 4 and week 8, which then dropped
back down to basal levels by week 12. The remaining swine did not display any significant
changes in serum HSP70i protein concentration.

CHAPTER 4
DISCUSSION
Because HSP70iQ435A inhibits the T cell-mediated auto-immune response against
melanocytes in vitiligo mouse models, there existed a valid concern that treatment with
this modified heat shock protein may also inhibit natural responses against melanocytederived melanoma tumor cells. As such, the first part of this project was to study the
effects of HSP70iQ435A DNA-treatment in a mouse melanoma model. The results from
these first two mouse studies indicated that not only was HSP70iQ435A not inhibitory of
anti-melanoma responses in mice, but DNA-treatment with both WT HSP70i and
HSP70iQ435A confer some degree of tumor resistance [Figure 1-3]. Regarding HSP70iQ435A
as a therapeutic agent for vitiligo treatment, these results are promising; vitiligo therapy
would be a step in the wrong direction if it decreased the patient’s immune response to
melanoma. This is especially relevant considering vitiligo is oftentimes a side-effect of
melanoma therapy as treatments targeting melanoma cells also collaterally target
melanocytes; as a result, vitiligo during melanoma therapy is sometimes considered a
good sign that the treatment is working (17). Staining results from these initial
experiments also show increased CD3 T cell counts around the periphery of the
melanoma tumor from mice that received either the WT HSP70i DNA-vaccination or the
38
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HSP70iQ435A when compared to the mice that received no treatment [Figure 13]. This is
compared to previous studies which observed decreased T cell infiltration in healthy and
vitiligo-affected skin after mice were vaccinated with HSP70iQ435A (Reference 4, Figure 3).
These results suggest that DNA-treatment with HSP70iQ435A can promote T cell presence
at the melanoma, while decreasing T cell presence at lesional vitiligo skin. Taken together,
this information seems to imply separate mechanisms by which HSP70iQ435A DNAtreatment might be inhibiting the auto-immune response against melanocytes and
promoting the anti-tumor response to melanoma.
Knowing that melanoma and other tumor cells overexpress and externally present
stress induced heat shock proteins such as HSP70i (7), we wanted to test the antibody
response to purified HSP70i protein after vaccination with either the WT HSP70i or
HSP70iQ435A. After running a Western with purified HSP70i and probing with sera
harvested from the mice in the previous experiments outline in Aim I: Sub-Aim I, the
results suggested that a DNA-treatment with WT HSP70i and HSP70iQ435A can promote
production of antibody against HSP70i and as such may be promoting anti-melanoma
responses via antibody-dependent cell-mediated cytoxicity (ADCC). Previous studies have
targeted membrane-bound HSP70 as a means of inducing ADCC killing of tumor cells,
where tumor growth was reduced in mice treated with antibody specific to an HSP70
epitope frequently detected on the surface of tumor cells (18). Results from the adoptive
transfer experiment outlined in Aim II: Sub-Aim I seem to coincide with those studies and
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suggest that antibody-mediation may indeed be the cause of this tumor inhibition. Tumor
challenged BL/6 mice that received B cells from HSP70i DNA-vaccinated BL/6 mice
displayed markedly smaller tumors, suggesting the B cell transfer was responsible for the
tumor inhibition [Figure 11]. To further test this, B cells taken from vaccinated BL/6 mice
were adoptively transferred into tumor-challenged, immuno-deficient SCID-beige mice.
Strangely, however, results showed decreased tumor growth in all mice that received B
cell injections, even the mice that received no HSP70i DNA-treatment [Figure 12];
however, there was no significance between the vaccinated and unvaccinated tumors.
Considering that SCID-beige strain is immuno-deficient of B and T cells, while still
containing defective NK cells, it might be possible that antibody from these adoptively
transferred B cells may still be enough to activate the NK cells in SCID-beige mice
(although this does not explain why the adoptive transfers from non-vaccinated mice are
doing so). Adoptive transfers of sensitized and primed B cells have previously been shown
to promote humoral anti-tumor responses in mice, where the adoptive transfer resulted
in production of tumor-specific antibody and tumor cell lysis in the presence of
complement (19). As SCID-beige mice contain normal complement levels, it is likely that
complement-dependent cytotoxic killing of tumor cells played a role in both of the
adoptive transfers.
A separate vaccination and tumor challenge experiment was also done on PMEL1 mice. These mice were chosen as they have transgenic T cell receptors specific to the
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mouse homologue (pmel-17) of human gp100, a melanocytic protein involved in pigment
synthesis. They naturally depigment which makes this strain a good choice for a vitiligo
mouse model; however it can take up to several months for any natural depigmentation
to occur. For this reason, the mice used in Aim I: sub-aim II were also vaccinated with the
DNA encoding gp100 to facilitate and speed up the depigmentation, alongside either the
WT HSP70i DNA and HSP70iQ435A DNA. Results from the tumor growth and final tumor
mass once again suggest anti-tumor responses mediated by treatment with an HSP70i
DNA-vaccine are not affected by the Q435A mutation in the stress protein [Figure 6, Figure
5]. As for the depigmentation results, mice treated with DNA encoding HSP70iQ435A display
slightly decreased average depigmentation at the end of the experiment when compared
to mice treated with DNA encoding WT HSP70i [Figure 7, Figure 8]. These data don’t quite
coincide with data from previous depigmentation studies, where the depigmentation was
significantly decreased in mice treated with DNA encoding HSP70iQ435A; it’s likely that the
addition of DNA encoding gp100 during the gene-gun vaccinations may have caused this
inconsistency and largely overruled the dampening effects of HSP70iQ435A, facilitating
depigmentation a lot more than we originally bargained for. Future studies will likely omit
or reduce the gp100 treatment, assuming that time is not a constraint as it was during
this study. Additionally, this study where treatment with gp100 is done alongside
HSP70iQ435A may prove useful in future trials related to gp100 treatment; as clinical trials
have already demonstrated gp100 as a successful melanoma antigen to target for
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melanoma therapy (20, 21) there will likely be a demand for secondary or additional
primary treatments to deter the vitiligo that develops as a result of the patient’s immune
system targeting melanocytic gp100.
To set the stage for further developments of HSP70iQ435A as a treatment for
autoimmune side effects of melanoma immunotherapy, we chose to test the efficacy of
these treatments on a swine model of vitiligo. This substrain of Sinclair miniature swine
is unique in that the swine spontaneously develop melanoma at a young age and, as the
melanoma regresses, they develop vitiligo as a side-effect (usually seen as a ring of
depigmented skin around the regressing melanoma). It should also be noted that 2 out of
the 4 swine that were sent to us did not have visible lesions of vitiligo which complicated
things in terms of analyzing the results. We used the DNA treatment on the 2 swine that
had visible vitiligo, and the PBS control treatment on the two swine that did not have
visible vitiligo (PBS injections were performed at a site of melanoma on these 2 swine).
The data seems to indicate a positive response from the DNA treatment in the first swine
[Figures 15a, 17a, 18ab] while there was not as much of a response in the second DNA
treated swine [Figures 15c, 17c, 18cd]. However, we must also consider that any area of
regressing vitiligo would see increasing levels of infiltrating T cells, and the maintenance
of a steady level in DNA Swine #2 may be indicative of a positive response to the
treatment. These swine are incredibly diverse when compared to a strain of lab mouse,
and variation in response to any experimental treatment is not unexpected. However, it
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is very promising to see the treatment working the way it is meant to be working in the
first DNA treated pig, and watching the T cell counts around the lesion decrease as the
lesion itself decreases in size and begins to repigment. Furthermore, one of the
milestones we had set for the trial included a 50% reduction in T cell infiltration which
was observed in the Group #1 swine treated with DNA, with a 75% decrease in CD3+ T
cells between the first week and the eight week; even comparing the first week with the
final week, there is still a 58% decrease [Figure 15a]. The data from the two ELISAs [Figures
17, 18] seems to suggest that the second swine did respond but in a different manner
than the first swine; where the first swine managed to divert the cytotoxic response away
from the treated area, the second swine began producing antibody against HSP70i.
Unfortunately, it’s still too early to judge what effect this might have on the swine’s antimelanoma responses but it will definitely be interesting to follow.
Conclusive Remarks
The results from these studies support the ongoing development of a novel
therapeutic that not only has the ability to restrict with the autoimmune responses that
cause vitiligo, but also maintain anti-tumor responses at the same time. Treatment with
HSP70iQ435A helps inhibit the cytotoxic auto-immune response against healthy
melanocytes, does not interfere with anti-tumor responses to melanoma cells, and also
seems to support anti-melanoma responses by stimulating production of anti-HSP70i
antibody which are able to direct antibody dependent cell-mediated cytotoxic responses
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against the HSP70i-saturated melanoma cells; these mechanisms are summarized in
Figure 19.

Figure 19: Mutant HSP70iQ435A promotes anti-tumor immunity while preventing autoimmunity.

(1) In vitiligo, stress to healthy melanocytes induces synthesis of HSP70i which is
(2) secreted from live cells through an active-release mechanism. These secreted HSP70i
proteins can potentially be chaperoning misfolded melanocytic proteins that are in the
process of refolding within the cell and, once in the extracellular environment, (3) bind to
and activate local dendritic cells to an inflammatory phenotype. These dendritic cells
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move through the draining lymph nodes where they (4) present melanocyte antigen to T
cells and stimulate a (5) melanosomal-ag specific CD8+ T cell cytotoxic response that
results in melanocyte destruction and depigmentation characteristic of vitiligo. When
HSP70iQ435A is introduced to the early steps of the system, a single amino acid change
(Glutamine to Alanine) in the DC-binding region of HSP70i is sufficient to deter (3) DC
activation to an inflammatory phenotype, instead inducing a non-inflammatory
phenotype which do not process and present melanocyte antigen. B cells in the lymph
are presented with DC-bound HSP70i and, upon recognition, proliferate and produce
HSP70i-specific antibody. (6) These antibodies recognize and bind surface HSP70i on
melanoma cells; CD16+ natural killer cells then bind the Fc region of the antibody,
stimulating the NK cell to release perforin, forming lytic pores in the melanoma, and
granzyme to induce apoptosis in the targeted melanoma cell.
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